HAIKOU,
China, Dec. 15, 2022 /PRNewswire/
-- China Pharma Holdings, Inc. (NYSE American: CPHI)
("China Pharma", the "Company" or "We"), an NYSE American-listed
corporation with a fully-integrated specialty pharmaceuticals
subsidiary based in China, today
announced that its drugs were listed in The Catalogue of
Medicines for People Infected with COVID-19 (First Edition)
(hereinafter referred to as the Catalogue) published by People's
Daily on December 12, 2022.
Recently, China has completely
ended its strict quarantine and zero case policies in response to
COVID-19 pandemic in the past three years. Out of concern about the
spread of the epidemic, people began to hoard many related drugs.
The Chinese government has issued the Catalogue to guide people to
take drugs accordingly. A series of drugs of our Company are listed
in the catalog, and the demand is huge.
- Our modern Traditional Chinese Medicine (TCM) anti-virus
product: Andrographolide has been listed in the Catalogue
- Our cold medicine: Naproxen Sodium and Pseudoephedrine
Hydrochloride Sustained Release Tablets (brand name, Pusen OK), in
which the compound ingredient pseudoephedrine is in line with the
cold symptom relief medicine recommended in the Catalog
- It was announced in many places in China in recent days that pharmacies will no
longer register or upload customer information on "four types of
drugs", which includes anti-fever, cough, antiviral and antibiotic
drugs. This will benefit the sales of our main products,
roxithromycin and cefaclor
- The market demand for our masks has also increased
significantly
Ms. Li Zhilin, CEO of China
Pharma said: " With the liberalization of epidemic risk control
measures across China, the number
of infected people may rise rapidly. The public's need in keeping
certain epidemic prevention materials and related drugs has been
dramatically increasing. As a professional pharmaceutical
manufacturer for nearly 30 years, we will continue to spare no
effort to provide high-quality products to protect people's
health."
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. (NYSE American: CPHI) is a specialty
pharmaceutical company that develops, manufactures, and markets a
diversified portfolio of products, focusing on conditions with high
incidence and high mortality rates in China, including cardiovascular, CNS,
infectious, and digestive diseases. The Company's cost-effective
business model is driven by market demand and supported by new
GMP-certified product lines covering the major dosage forms. In
addition, the Company has a broad and expanding nationwide
distribution network across all major cities and provinces in
China. The Company's wholly-owned
subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd.,
is located in Haikou City,
Hainan Province. For more
information about China Pharma Holdings, Inc., please visit
www.chinapharmaholdings.com. The Company routinely posts important
information on its website.
Safe Harbor Statement
Certain statements in this press release constitute
forward-looking statements for purposes of the safe harbor
provisions under The Private Securities Litigation Reform Act of
1995. Any statements set forth above that are not historical facts
are forward-looking statements that involve risks and uncertainties
that could cause actual results to differ materially from those in
the forward-looking statements. Such risks and uncertainties may
include, but are not limited to: the achievability of financial
guidance; success of new product development; unanticipated changes
in product demand; increased competition; downturns in the Chinese
economy; uncompetitive levels of research and development; and
other information detailed from time to time in the Company's
filings and future filings with the United States Securities and
Exchange Commission. The forward-looking statements made herein
speak only as of the date of this press release and the Company
undertakes no duty to update any forward-looking statement to
conform the statement to actual results or changes in the Company's
expectations, except as required by applicable law or
regulation.
View original
content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc-announced-that-several-products-are-included-in-the-catalogue-of-medicines-for-people-infected-with-covid-19-301703828.html
SOURCE China Pharma Holdings, Inc.